A groundbreaking discovery has the potential to revolutionize kidney disease treatment, but it's sparking intense debate among healthcare professionals. Should a metabolic drug be routinely used for all kidney function levels?
Two extensive studies reveal that sodium-glucose co-transporter 2 (SGLT2) inhibitors significantly lower the risk of kidney disease progression, hospitalization, and even death in individuals with or without diabetes, regardless of their kidney function. This is a game-changer, as these findings were presented at the American Society of Nephrology Kidney Week and published in JAMA, backed by data from over 70,000 participants in 10 major trials.
SGLT2 inhibitors, initially designed for type 2 diabetes, have proven to be a powerful defense against heart failure and chronic kidney disease (CKD). However, their effectiveness in advanced CKD cases and individuals with low albuminuria (protein in urine, indicating early kidney issues) has been a topic of uncertainty. But here's where it gets controversial—the studies show that these inhibitors work across all kidney function levels and albuminuria rates.
In one analysis, SGLT2 inhibitors reduced CKD progression by a remarkable 38% compared to placebos, regardless of kidney function measured by estimated glomerular filtration rate (eGFR). They slowed the annual eGFR decline by 51%, benefiting even those with stage 4 CKD and minimal or no albuminuria, groups previously lacking clear treatment guidelines.
The second study focused on diabetes status and albuminuria levels, finding significant benefits for all patients, especially in reducing hospitalizations. Heart failure-related hospitalizations decreased by a third in diabetic patients and a quarter in non-diabetic patients, with low risks of adverse events.
Associate Professor Brendon Neuen, from The George Institute, emphasizes that these findings advocate for the widespread use of SGLT2 inhibitors in CKD patients. He believes this could significantly reduce kidney failure, hospitalization, and premature deaths, benefiting a broader population than currently treated.
CKD affects approximately 850 million people worldwide and is a leading cause of mortality and disability. The SMART-C consortium, co-chaired by Professor Neuen and Professor Hiddo Heerspink, aims to address this global health challenge by advocating for increased access to SGLT2 inhibitors, especially in low- and middle-income countries.
But the question remains: should these inhibitors be a routine treatment for all kidney function levels? The evidence is compelling, but the medical community is divided. What's your take on this controversial topic? Share your thoughts in the comments below!
